Dermapharm Holding SE
DMPGermany
31 filed reports · 191 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Latest quarter
Filed reports
31 reports · Sep 2017 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Half YearBundesanzeiger | 9 | 776 | Jun 2018 to Jun 2026 |
| Q3Bundesanzeiger | 9 | 576 | Sep 2017 to Sep 2025 |
| Q1Bundesanzeiger | 8 | 587 | Mar 2019 to Mar 2026 |
| AnnualBundesanzeiger | 5 | 348 | Dec 2021 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | half year | 2026-06-30 | 2026-06-30 | 111 | Open |
| FY2026 Q1 | q1 | 2026-03-31 | 2026-03-31 | 87 | Open |
| FY2025 | annual | 2025-12-31 | 2025-12-31 | 70 | Open |
| FY2025 Q3 | q3 | 2025-09-30 | 2025-09-30 | 70 | Open |
| FY2025 Q2 | half year | 2025-06-30 | 2025-06-30 | 45 | Open |
| FY2025 Q1 | q1 | 2025-03-31 | 2025-03-31 | 69 | Open |
| FY2024 | annual | 2024-12-31 | 2024-12-31 | 71 | Open |
| FY2024 Q3 | q3 | 2024-09-30 | 2024-09-30 | 72 | Open |
| FY2024 Q2 | half year | 2024-06-30 | 2024-06-30 | 88 | Open |
| FY2024 Q1 | q1 | 2024-03-31 | 2024-03-31 | 42 | Open |
| FY2023 | annual | 2023-12-31 | 2023-12-31 | 69 | Open |
| FY2023 Q3 | q3 | 2023-09-30 | 2023-09-30 | 44 | Open |
Financial data
191 concepts · 2,287 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS179 concepts · 2,086 facts · Sep 2017 to Jun 2026
- Stockholders Equity45 · Dec 2017 to Jun 2026
- Operating Income33 · Jun 2018 to Jun 2026
- Total Assets32 · Sep 2017 to Jun 2026
- Total Current Assets32 · Dec 2017 to Jun 2026
- Total Current Liabilities32 · Dec 2017 to Jun 2026
- Total non-current assets31 · Dec 2017 to Jun 2026
- Accounts Payable30 · Jun 2018 to Jun 2026
- Cash and Equivalents30 · Sep 2017 to Jun 2026
- Current financial liabilities30 · Dec 2017 to Jun 2026
- Equity investments30 · Jun 2018 to Jun 2026
- Goodwill30 · Jun 2018 to Jun 2026
- Intangible Assets (excluding Goodwill)30 · Jun 2018 to Jun 2026
- Inventory30 · Jun 2018 to Jun 2026
- Investments accounted for using the equity method30 · Jun 2018 to Jun 2026
- Non-current financial liabilities30 · Jun 2018 to Jun 2026
- Other provisions30 · Jun 2018 to Jun 2026
- Property, Plant & Equipment, Net30 · Jun 2018 to Jun 2026
- Revenue30 · Jun 2018 to Jun 2026
- Total non-current liabilities30 · Dec 2017 to Jun 2026
- Accounts Receivable, Net29 · Jun 2018 to Jun 2026
- Capital reserves29 · Jun 2018 to Jun 2026
- Other current financial assets29 · Dec 2017 to Jun 2026
- Other non-current financial assets29 · Sep 2018 to Jun 2026
- Deferred tax liabilities28 · Jun 2018 to Jun 2026
Segment9 concepts · 177 facts · Jun 2018 to Jun 2026
- EBITDA margin37 · Jun 2018 to Jun 2026
- EBITDA (unadjusted)30 · Jun 2018 to Jun 2026
- Reported revenue in the “Parallel import business“ segment30 · Jun 2018 to Jun 2026
- Revenue30 · Jun 2018 to Jun 2026
- of which intersegment revenue17 · Sep 2018 to Jun 2026
- of which earnings from investments accounted for using the equity method12 · Sep 2018 to Jun 2026
- Revenue from external customers9 · Mar 2021 to Mar 2022
- Cost of materials6 · Mar 2026 to Jun 2026
- Personnel expenses6 · Mar 2026 to Jun 2026
KPI1 concept · 15 facts · Mar 2021 to Dec 2025
- Equity ratio15 · Mar 2021 to Dec 2025
APM2 concepts · 9 facts · Jun 2018 to Sep 2020
- EBITDA8 · Jun 2018 to Sep 2020
- non-recurring expenses and provisions1 · Sep 2020
Segments
177 factsFigures broken down by business line, region, product or another axis the company reports on.
Business segment7 members · 177 facts
- Parallel import business53 · Jun 2018 to Jun 2026
- Branded pharmaceuticals and other healthcare products50 · Jun 2018 to Mar 2022
- Herbal extracts37 · Mar 2019 to Mar 2022
- Branded pharmaceuticals15 · Mar 2026 to Jun 2026
- Other healthcare products14 · Mar 2026 to Jun 2026
- Parallel imports4 · Jun 2018
- Pharmaceuticals and other healthcare products4 · Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Dermapharm Holding SE (DMP) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.